Systemic Sclerosis Market Size in Japan is Projected to Grow Significantly by 2036, Estimates DelveInsight

The market dynamics for Systemic Sclerosis (SSc) are witnessing substantial growth driven by increasing disease prevalence, rising patient awareness, improved diagnosis rates, and the launch of emerging therapies with novel mechanisms of action. Growing understanding of inflammatory-fibrotic pathways, advancements in biologic therapies, and increased focus on personalized medicine approaches are further supporting market expansion. Additionally, the development of promising therapies such as SAPHNELO (AstraZeneca), UPLIZNA (Mitsubishi Tanabe Pharma), Avenciguat (Boehringer Ingelheim), and others is expected to reshape the Systemic Sclerosis treatment landscape during the forecast period.

DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of Systemic Sclerosis, historical and forecasted epidemiology, as well as the Systemic Sclerosis market trends in Japan.

Discover which therapies are expected to grab the https://www.delveinsight.com/sample-request/systemic-sclerosis-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the Systemic Sclerosis Market Report
• The Systemic Sclerosis market size in Japan is expected to grow significantly during the forecast period (2026-2036).
• According to DelveInsight estimates, the total market size of Systemic Sclerosis in Japan is expected to increase substantially by 2036.
• In 2025, DelveInsight estimates indicated that mild systemic sclerosis cases characterized by limited skin thickness accounted for approximately 74% of cases in Japan, while moderate and severe cases represented nearly 26%.
• According to Kuwana et al. (2022), the overall prevalence of Systemic Sclerosis per 100,000 persons was 37.0, while Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) prevalence was 13.9 per 100,000 persons.
• Gastroesophageal reflux disease (GERD) represents one of the predominant organ manifestations in systemic sclerosis, followed by musculoskeletal involvement and interstitial lung disease.
• The leading Systemic Sclerosis companies such as Mitsubishi Tanabe Pharma, AstraZeneca, GlaxoSmithKline, Novartis, Boehringer Ingelheim, Bristol-Myers Squibb, and others are actively developing novel therapies.
• Promising Systemic Sclerosis pipeline therapies such as Inebilizumab, Anifrolumab, Avenciguat, Belimumab, Ianalumab, and others are expected to transform the treatment landscape.

Stay ahead in the Systemic Sclerosis Therapeutics Market with DelveInsight's Strategic Report.
https://www.delveinsight.com/sample-request/systemic-sclerosis-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Systemic Sclerosis?
Systemic sclerosis (SSc), also known as scleroderma, is a chronic autoimmune connective tissue disease characterized by fibrosis of the skin and internal organs, vascular abnormalities, and immune system dysregulation. The disease can affect multiple organs including the lungs, gastrointestinal tract, kidneys, heart, and musculoskeletal system.

Diffuse cutaneous systemic sclerosis is generally more severe and associated with higher mortality compared to limited cutaneous systemic sclerosis due to greater internal organ involvement. Systemic sclerosis predominantly affects women between 30-60 years of age and is associated with substantial morbidity and mortality.

Current treatment strategies primarily focus on managing organ-specific complications and slowing disease progression through immunosuppressive agents, antifibrotic therapies, and biologics.

Systemic Sclerosis Epidemiology Segmentation
• Total Diagnosed Prevalent Cases of Systemic Sclerosis
• Systemic Sclerosis by Disease Subset
• Age-specific Cases of Systemic Sclerosis
• Systemic Sclerosis with Organ Involvements
• Systemic Sclerosis Severity by Organ Damage
• Systemic Sclerosis Severity by Skin Thickness

Download the report to understand which factors are driving https://www.delveinsight.com/sample-request/systemic-sclerosis-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Systemic Sclerosis Marketed Drugs

OFEV (nintedanib): Boehringer Ingelheim
OFEV is a tyrosine kinase inhibitor that works by blocking enzymes involved in fibrosis. The therapy is approved for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD). In December 2019, OFEV received approval in Japan for SSc-ILD.

RITUXAN (rituximab): Zenyaku Kogyo/Chugai Pharmaceutical
RITUXAN is an anti-CD20 monoclonal antibody targeting B cells involved in autoimmune responses. In September 2021, the Ministry of Health, Labour and Welfare (MHLW) approved RITUXAN for systemic sclerosis in Japan.

Systemic Sclerosis Drugs and Companies
• AstraZeneca: SAPHNELO (anifrolumab)
• Mitsubishi Tanabe Pharma: UPLIZNA (inebilizumab)
• Boehringer Ingelheim: Avenciguat (BI 685509)
• GlaxoSmithKline: Belimumab
• Novartis: Ianalumab
• Bristol-Myers Squibb: Zolacaptagene autoleucel

To learn more about Systemic Sclerosis treatment guidelines, visit DelveInsight.

Key Factors Driving the Systemic Sclerosis Market
• Increasing prevalence and awareness of systemic sclerosis: Rising recognition of systemic sclerosis and improved diagnostic approaches are contributing to greater disease identification and treatment rates.
• Advancements in biologic and antifibrotic therapies: Novel therapies targeting inflammatory and fibrotic pathways are improving disease management and expanding therapeutic options.
• Growing focus on personalized medicine: Tailored treatment strategies based on disease subtype, organ involvement, and severity are expected to optimize patient outcomes.
• Expanding pipeline of emerging therapies: Strong clinical development activities involving biologics, immunotherapies, and targeted therapies are expected to drive future market growth.
• Improved survival and supportive care: Better management of organ complications and advances in supportive therapies are improving long-term patient outcomes.

Recent Developments in the Systemic Sclerosis Market
• In 2024, the US FDA granted Fast Track Designation to Avenciguat for the treatment of systemic sclerosis.
• Mitsubishi Tanabe Pharma obtained licensing rights for UPLIZNA from Viela Bio for development and commercialization across Japan and several Asian countries.
• In September 2021, RITUXAN received approval from Japan's MHLW for systemic sclerosis treatment.
• SAPHNELO (anifrolumab) is currently being evaluated in the Phase III DAISY study (NCT05925803) for adult patients with systemic sclerosis.
• In severe systemic sclerosis cases, hematopoietic stem cell transplantation (HSCT) has demonstrated positive effects on survival, pulmonary involvement, and quality of life.

Scope of the Systemic Sclerosis Market Report
• Coverage: Japan
• Study Period: 2022-2036
• Systemic Sclerosis Companies: Mitsubishi Tanabe Pharma, AstraZeneca, GlaxoSmithKline, Novartis, Boehringer Ingelheim, Bristol-Myers Squibb, and others
• Systemic Sclerosis Pipeline Therapies: Inebilizumab, Anifrolumab, Avenciguat, Belimumab, Ianalumab, and others
• Systemic Sclerosis Market Dynamics: Market Drivers and Barriers
• Systemic Sclerosis Market Access and Reimbursement
• Systemic Sclerosis Unmet Needs and Future Perspectives

Discover more about Systemic Sclerosis drugs in development.
https://www.delveinsight.com/sample-request/systemic-sclerosis-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
• Systemic Sclerosis Market Report Introduction
• Executive Summary of Systemic Sclerosis
• SWOT Analysis of Systemic Sclerosis
• Systemic Sclerosis Market Overview at a Glance
• Disease Background and Overview
• Systemic Sclerosis Epidemiology and Patient Population
• Country-Specific Patient Population of Systemic Sclerosis
• Systemic Sclerosis Current Treatment and Medical Practices
• Systemic Sclerosis Unmet Needs
• Systemic Sclerosis Emerging Therapies
• Systemic Sclerosis Market Outlook
• Market Size Analysis of Systemic Sclerosis in Japan (2022-2036)
• Systemic Sclerosis Market Access and Reimbursement
• Systemic Sclerosis Market Drivers
• Systemic Sclerosis Market Barriers
• Systemic Sclerosis Appendix
• Systemic Sclerosis Report Methodology
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.